Later studies demonstrated that FOXM1 overexpression leads to resistance to gefitinib, an EGFR small molecule inhibitor used as first-line therapy to treat NSCLC in lung cancer cell lines and primary human lung cancer cells. This evidence concerns the gene FOXM1 and non-small cell lung carcinoma.